Patient specific dosing in a cancer phase I clinical trial

James S. Babb, André Rogatko

Type: Article

Publication Date: 2001-06-28

Citations: 89

DOI: https://doi.org/10.1002/sim.848

View Publication

Locations

PubMed - View
Statistics in Medicine - View

Similar Works

Action	Title	Year	Authors
+ PDF Chat	New Paradigm in Dose-Finding Trials: Patient-Specific Dosing and Beyond Phase I	2005	André Rogatko James S. Babb Mourad Tighiouart Fadlo R. Khuri Gary R. Hudes
+	Phase I Trials including Phase I Cancer Trials	2014	Sylvie Chevret
+ PDF Chat	The rationale of dose–response curves in selecting cancer drug dosing	2019	Jennifer Martin Simon B. Dimmitt
+	Phase I Trial Design and Methodology	1997	Deborah Toppmeyer
+	Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology	2003	Ch. van Kesteren Ron A. A. Mathôt Jos H. Beijnen Jan H.M. Schellens
+	A Survey of the Way Pharmacokinetics are Reported in Published Phase I Clinical Trials, with an Emphasis on Oncology	2009	Emmanuelle Comets Sarah Zohar
+	New Adaptive Method for Phase I Trials in Oncology	2007	Christophe Meille J.C. Gentet Dominique Barbolosi Nicolás André François Doz Athanassios Iliadis
+ PDF Chat	A Brief Overview of Adaptive Designs for Phase I Cancer Trials	2022	Anshul Saxena Muni Rubens Venkataraghavan Ramamoorthy Zhenwei Zhang Md Ashfaq Ahmed Peter McGranaghan Sankalp Das Emir Veledar
+	Phase I Trials in Special Populations and Circumstances	2015	Kumar Rajiv Twelves Chris Udai Banerji
+	Pharmacodynamic Modeling	2013	Kenneth S. Bauer Fatemeh Tavakkoli
+	Phase I Cancer Clinical Trials: A Practical Guide	2006	Elizabeth A. Eisenhauer Christopher Twelves Marc Buyse
+	Phase I Dose-Finding Designs and Their Applicability to Targeted Therapies	2015	Takashi Daimon Akihiro Hirakawa Shigeyuki Matsui
+ PDF Chat	Practical designs for Phase I combination studies in oncology	2015	Nolan A. Wages Anastasia Ivanova Olga Marchenko
+	Adaptive oncology phase I trial design of drug combinations with drug-drug interaction modeling	2017	Yang Yang Hong‐Bin Fang Anindya Roy Ming Tan
+	Phase I Trials	2008	Sylvie Chevret
+	Mise en place et spécificités des études cliniques de phase I en cancérologie	2015	Aurélie Labesque
+ PDF Chat	Adaptive clinical trial designs for phase I cancer studies	2014	Oleksandr Sverdlov Weng Kee Wong Yevgen Ryeznik
+	Statistical Designs for First-in-Man Phase I Cancer Trials	2015	Xavier Paolettí Marc Buyse
+	Principles of Dose, Schedule, and Combination Therapy	2017	William N. Hait Joseph P. Eder
+	A design for phase II testing of anticancer agents within a phase III clinical trial	1988	Daniel J. Schaid James N. Ingle Sam Wieand David L. Ahmann

Works That Cite This (82)

Action	Title	Year	Authors
+ PDF Chat	Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers	2021	Shinjo Yada
+ PDF Chat	The Bayesian Design of Adaptive Clinical Trials	2021	Alessandra Giovagnoli
+ PDF Chat	Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control	2012	Mourad Tighiouart Galen Cook‐Wiens André Rogatko
+ PDF Chat	Bayesian statistics in medicine: a 25 year review	2006	Deborah Ashby
+ PDF Chat	A Bayesian adaptive design for cancer phase I trials using a flexible range of doses	2017	Mourad Tighiouart Galen Cook‐Wiens André Rogatko
+	Ethical and Design Issues of Phase I Clinical Trials in Cancer Patients	2007	Hans Grünwald
+	A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes	2020	Yifei Zhang Sha Cao Chi Zhang Ick Hoon Jin Yong Zang
+	Systematic comparison of the statistical operating characteristics of various Phase I oncology designs	2016	Revathi Ananthakrishnan Stephanie Green Mark Chang Gheorghe Doros Joseph M. Massaro Michael P. LaValley
+	Two-stage Continual Reassessment Method and Patient Heterogeneity for Dose-finding Studies	2014	Xiaoyu Jia
+ PDF Chat	Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials	2015	Zhengjia Chen Ying Yuan Li Zheng Michael Kutner Taofeek K. Owonikoko Walter J. Curran Fadlo R. Khuri Jeanne Kowalski

Works Cited by This (13)

Action	Title	Year	Authors
+	TWO-SAMPLE CONTINUAL REASSESSMENT METHOD	1999	John O’Quigley Larry Z. Shen Anthony Gamst
+	Pharmacologically Guided Phase I Clinical Trials Based Upon Preclinical Drug Development	1990	Jerry M. Collins Charles K. Grieshaber Bruce A. Chabner
+	Cancer phase I clinical trials: efficient dose escalation with overdose control	1998	James S. Babb André Rogatko Shelemyahu Zacks
+	Sequential Search of an Optimal Dosage, I	1973	B. H. Eichhorn S. Zacks
+	Optimal Bayesian-feasible dose escalation for cancer phase I trials	1998	S. Zacks André Rogatko James S. Babb
+	Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer	1990	John O’Quigley Margaret S. Pepe Lloyd D. Fisher
+	IMPROVED DESIGNS FOR DOSE ESCALATION STUDIES USING PHARMACOKINETIC MEASUREMENTS	1996	Steven Piantadosi G. Frank Liu
+	Statistical and Ethical Issues in the Design and Conduct of Phase I and II Clinical Trials of New Anticancer Agents	1993	Mark J. Ratain Rosemarie Mick Richard L. Schilsky Mark Siegler
+	Model-Guided Determination of Maximum Tolerated Dose in Phase I Clinical Trials: Evidence for Increased Precision	1993	Rosemarie Mick MJ Ratain
+	Responses and toxic deaths in Phase I clinical trials	1990	Genevieve Decoster Gerburg M. Stein E. E. Holdener